Fasting and Cancer Therapy: Does It Help Treatment?

Fasting and Cancer Therapy: What Studies Show

Fasting and Cancer Therapy: What Studies Show. Can eating less actually help cancer treatment work better?

For decades, cancer patients were told to “keep your strength up” by eating as much as possible during treatment. Today, researchers are investigating a very different question:

Could carefully timed fasting actually make chemotherapy work better while reducing side effects?

The answer is possibly—but not for everyone.

Animal studies have produced remarkably encouraging results, and early human clinical trials suggest that short-term fasting and fasting-mimicking diets (FMDs) may reduce chemotherapy toxicity while improving the body’s immune and metabolic response to treatment. However, the evidence is still emerging, and fasting should never replace evidence-based cancer therapy.

As a long-term multiple myeloma survivor, I’ve learned that many complementary therapies have a strong biological rationale but require careful interpretation. Fasting is one of them.

Scroll down the page and post a question or a comment if there’s anything you’d like to know about breast cancer.

Good luck,

David Emerson

What happens to cancer cells when you fast for 24 hours?

Quick Answer

Current research suggests that:

Short-term fasting before chemotherapy may reduce certain treatment side effects
Fasting-mimicking diets appear safer and more practical than complete fasting
Animal studies consistently show enhanced chemotherapy effectiveness
Human trials are encouraging but still relatively small
Larger randomized clinical trials are underway
Fasting is not appropriate for every patient

Why Researchers Became Interested in Fasting

Cancer cells have an enormous demand for nutrients.

Many cancers depend heavily on:

Glucose
Insulin
IGF-1 (Insulin-like Growth Factor-1)
Amino acids
Growth signaling pathways such as mTOR

When food intake temporarily decreases:

insulin falls
IGF-1 decreases
mTOR activity drops
autophagy increases
healthy cells shift into a protected “maintenance mode”

Cancer cells often cannot make this same metabolic adjustment because many have permanently activated growth pathways.

Researchers call this concept:

Differential Stress Resistance

Healthy cells become more resistant to chemotherapy while cancer cells remain vulnerable. This mechanism has been demonstrated repeatedly in laboratory studies.

What Is a Fasting-Mimicking Diet?

Most modern cancer studies do not ask patients to stop eating completely.

Instead, they use a fasting-mimicking diet (FMD).

Typical characteristics include:

Very low calories (approximately 300–600 kcal/day)
Mostly plant-based
Low protein
Low sugar
Low carbohydrate
Usually lasts five days
Timed around chemotherapy

The goal is to trigger fasting-related metabolic changes while maintaining better safety and tolerability than water-only fasting.

What Animal Studies Show

Animal research has been remarkably consistent.

Researchers have observed:

slower tumor growth
increased chemotherapy sensitivity
enhanced immunotherapy activity
reduced DNA damage in healthy tissues
increased cancer cell death
improved immune-cell infiltration into tumors
longer survival in multiple tumor models

These findings helped launch the current wave of human clinical trials.

What Human Studies Show

Human evidence is encouraging—but much less definitive.

Across early clinical trials, fasting or fasting-mimicking diets have been associated with:

Reduced chemotherapy side effects

Patients often reported less:

fatigue
nausea
weakness
gastrointestinal symptoms

Several studies also found reduced markers of chemotherapy-induced cellular damage.

Better metabolic health

Researchers observed reductions in:

glucose
insulin
IGF-1

These metabolic changes may create an environment less favorable for cancer growth.

Improved immune response

Several studies found:

more activated T cells
fewer immunosuppressive immune cells
greater immune infiltration into tumors

These findings are especially interesting because they may improve responses to:

chemotherapy
immunotherapy
targeted therapy

However, this remains an active area of research.

What About Breast Cancer?

Breast cancer has the strongest human evidence so far.

The DIRECT trial evaluated fasting-mimicking diets during neoadjuvant chemotherapy.

The primary endpoints were not met, but investigators reported several encouraging findings:

reduced chemotherapy-related DNA damage in healthy lymphocytes
possible improvement in tumor response among patients who adhered well
good overall safety
high feasibility challenges because maintaining strict dietary adherence proved difficult

Researchers concluded that larger, better-designed trials are warranted rather than abandoning the approach.

Ongoing Clinical Trials

Numerous ongoing studies are evaluating fasting-mimicking diets with:

breast cancer
colorectal cancer
pancreatic cancer
prostate cancer
immunotherapy
chemotherapy combinations

Most are designed to answer whether fasting actually improves:

progression-free survival
overall survival
pathological response
immune activation
quality of life

These results will likely determine whether fasting becomes part of routine oncology care.

Who Should NOT Fast?

Fasting is not appropriate for everyone.

Patients generally should avoid fasting if they have:

cancer cachexia
unintended weight loss
malnutrition
BMI below recommended study thresholds
uncontrolled diabetes
frailty
eating disorders
pregnancy
severe kidney disease

Many fasting studies specifically excluded these patients because of safety concerns.

Who Should Consider Fasting?

May	a patient fasting be appropriate?
Healthy weight receiving chemotherapy	Possibly, under oncology supervision
Receiving immunotherapy	Being studied; discuss with oncology team
Overweight/metabolic syndrome	Potentially beneficial in some trials
Multiple myeloma patient with stable weight	Research is limited; discuss with hematologist
Cachexia or significant weight loss	Generally not recommended
Frail older adult	Usually not recommended
Uncontrolled diabetes	Requires close medical supervision
During stem cell transplant	Generally not recommended outside a clinical trial

Practical Takeaways

For most cancer patients, current evidence supports these principles:

Do not begin prolonged fasting on your own.
Discuss any fasting plan with your oncology team and, ideally, an oncology dietitian.
If fasting is considered, use structured, medically supervised protocols rather than unsupervised water-only fasting.
Maintain adequate protein and calorie intake between treatment cycles unless instructed otherwise.
Patients with weight loss or poor nutritional status generally benefit more from nutritional support than calorie restriction.

Bottom Line

Fasting is no longer considered a fringe idea in cancer research.

Scientists have identified compelling biological mechanisms that may explain why temporary calorie restriction could:

protect healthy cells
sensitize cancer cells
improve immune function
reduce chemotherapy toxicity

The strongest evidence currently supports short-term fasting-mimicking diets rather than prolonged fasting, and these approaches should be viewed as adjuncts—not substitutes—for standard cancer therapy.

Large randomized clinical trials are still needed before fasting can be routinely recommended, but the field is moving rapidly, and the results are worth following.

Research References

To Learn More:

Fasting and Cancer Therapy Fasting and Cancer Therapy

Our Mission